Xuzhou, China Clinical Trials

A listing of Xuzhou, China clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 4 clinical trials
CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies

CD19 expression on B cell frequently lost after CD19-targeting CAR-T therapy. In present study, we construct a CD22-targeting chimeric antigen receptor to overcome this issue.

Affiliated hospital of Xuzhou medical college
 (6.1 away) Contact site
  • 0 views
  • 08 Nov, 2020
  • 1 location
Combination Transfer of CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy

Clinical study of CD19 CAR-T in the treatment of blood and lymphatic system tumor has been achieved a breakthrough. The main solution in clinical research is to use CD19 CAR-T infusion alone. Because of the heterogeneity of the tumor, the patient often carries tumor cells with CD19 deficient but other …

lymphoma
leukemia
hematologic malignancy
cell transplantation
monoclonal antibodies
  • 40 views
  • 08 Nov, 2020
  • 1 location
Humanized CAR-T Therapy for Treatment of B Cell Malignancy

The present study evaluates the safety and efficacy of humanized Chimeric antigen receptor T cells (CAR-T) in treating recurrent or refractory B cell malignancy targeting CD19 with a humanized scFv. All participants will receive autologous chimeric antigen receptor engineered T cells.

cancer
hematologic malignancy
cell transplantation
Affiliated hospital of Xuzhou medical college
 (6.1 away) Contact site
  • 18 views
  • 08 Nov, 2020
  • 1 location
A Clinical Study to Evaluate Pharmacokinetics Safety and Tolerability of Abexinostat in Chinese Patients

This is an open-label, non-randomized clinical study to evaluate the pharmacokinetic (PK) profiles, safety, tolerability and preliminary efficacy of oral abexinostat monotherapy in patients with non-Hodgkin's lymphoma who have failed standard of care, and thereby to determine the pharmacokinetic (PK) parameters, the maximum tolerated dose (MTD), and the recommended phase …

blood transfusion
hodgkin's disease
The Affiliated Hospital of Xuzhou Medical University
 (7.5 away) Contact site
  • 2 views
  • 22 Jun, 2020
  • +3 other locations